AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: trademarks

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

Lucid Rolls Out Hands-Free Driving Assist and New Software Features for Lucid Gravity in North America

NEWARK, Calif., June 8, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ: LCID), maker of the world's most advanced software-defined vehicles and technologies, today announced...

GraniteShares Announces Forward Splits

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- GraniteShares has announced it will execute forward shares split for the several funds (the “Funds”). The total market value of the shares outstanding will not be affected as a result of these splits.

First Watch Restaurant Group, Inc. Announces Appointment of Ashlee Weisser to Chief Financial Officer

BRADENTON, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (Nasdaq: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Ashlee Weisser to Chief Financial Officer effective June 8, 2026. She succeeds Mel Hope, who announced his planned retirement earlier this year and will continue to serve in an Advisor role to support a seamless leadership transition.

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

New Linux Foundation Report Finds AI is Driving Positive Tech Hiring Trends in Europe Amid Growing Security and Skills Gaps

Increased AI deployment results in an aggregated net hiring effect of +27% expected in 2026, while upskilling internal talent emerges as the primary strategy...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrademarks